Takeda Pharmaceutical Co Ltd (TAK) stock saw a modest uptick, ending the day at $13.32 which represents a slight increase of $0.07 or 0.53% from the prior close of $13.25. The stock opened at $13.23 ...
Industry giants like Takeda Pharmaceuticals, Pfizer, Novartis, and Bayer are revolutionizing treatment landscapes, paving the way for enhanced patien ...
No, Bernie Sanders and Elizabeth Warren aren’t top recipients of pharmaceutical industry donations
A quirk in the website OpenSecrets has given RFK Jr. a chance to misleadingly portray Sen. Bernie Sanders as receiving big ...
Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...
Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...
Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback